Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data

被引：0
|
作者：
Hirohito Shimizu
Hisanori Kobayashi
Masayoshi Kanbori
Yutaka Ishii
机构：
[1] Janssen Pharmaceutical K.K,Medical Affairs Division, Immunology Department
[2] R&D Janssen Pharmaceutical K.K.,Clinical Science Division, External Collaboration and Portfolio Management Department
[3] Janssen Pharmaceutical K.K.,Japan Safety & Surveillance Division, Research & Development Division
来源：
Rheumatology and Therapy | 2020年 / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Under Results section, heading: Effectiveness of GLM Stratified by the Time to Dose Escalation, the remission based on values of DAS28, SDAI, and CDAI was published incorrectly. The correct values are: 16.1%, 5.0% and 4.3%
引用
收藏
页码：1053 / 1053
相关论文
共 50 条
  • [1] Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
    Shimizu, Hirohito
    Kobayashi, Hisanori
    Kanbori, Masayoshi
    Ishii, Yutaka
    RHEUMATOLOGY AND THERAPY, 2020, 7 (02) : 311 - 325
  • [2] Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
    Hirohito Shimizu
    Hisanori Kobayashi
    Masayoshi Kanbori
    Yutaka Ishii
    Rheumatology and Therapy, 2020, 7 : 311 - 325
  • [3] Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data (vol 7, pg 311, 2020)
    Shimizu, Hirohito
    Kobayashi, Hisanori
    Kanbori, Masayoshi
    Ishii, Yutaka
    RHEUMATOLOGY AND THERAPY, 2020, 7 (04) : 1053 - 1053
  • [4] Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data
    Mimori, Tsuneyo
    Harigai, Masayoshi
    Atsumi, Tatsuya
    Kuwana, Masataka
    Takei, Syuji
    Tamura, Naoto
    Fujii, Takao
    Matsuno, Hiroaki
    Momohara, Shigeki
    Yamamoto, Kazuhiko
    Kokubo, Takeshi
    Endo, Yutaka
    Sugiyama, Naonobu
    Hirose, Tomohiro
    Morishima, Yosuke
    Yoshii, Noritoshi
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [5] POST-MARKETING SURVEILLANCE OF TOFACITINIB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS: AN INTERIM REPORT OF SAFETY DATA
    Tamura, N.
    Kuwana, M.
    Atsumi, T.
    Takei, S.
    Harigai, M.
    Fujii, T.
    Matsuno, H.
    Mimori, T.
    Momohara, S.
    Yamamoto, K.
    Nomura, K.
    Endo, Y.
    Sugiyama, N.
    Hirose, T.
    Morishima, Y.
    Yoshii, N.
    Takagi, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1408 - 1408
  • [6] POST-MARKETING SURVEILLANCE OF TOFACITINIB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS: AN INTERIM REPORT OF SAFETY DATA
    Mimori, T.
    Harigai, M.
    Atsumi, T.
    Kuwana, M.
    Takei, S.
    Tamura, N.
    Fuji, T.
    Matsuno, H.
    Momohara, S.
    Yamamoto, K.
    Kokubo, T.
    Endo, Y.
    Sugiyama, N.
    Hirose, T.
    Morishima, Y.
    Yoshii, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1200 - 1201
  • [7] Relevant factors for dosing period of bexarotene treatment in Japanese patients with mycosis fungoides: A post-hoc analysis from accumulated post-marketing surveillance data
    Hamada, T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S102 - S102
  • [8] Investigation of the predictors of the response to Iguratimod therapy: A post-hoc analysis of post-marketing surveillance study
    Ishiguro, Naoki
    Shibata, Kai
    Yoshimura, Akiko
    Ikeuchi, Satoshi
    Ishii, Mika
    MODERN RHEUMATOLOGY, 2020, 30 (04) : 626 - 632
  • [9] Post-marketing surveillance of high-dose methotrexate (>8 mg/week) in Japanese patients with rheumatoid arthritis: A post hoc sub-analysis of patients according to duration of prior methotrexate use
    Suzuki, Yasuo
    Hirose, Tomohiro
    Sugiyama, Noriko
    Nomura, Kazuto
    Campos-Alberto, Eduardo
    MODERN RHEUMATOLOGY, 2021, 31 (03) : 575 - 586
  • [10] Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
    Gerd R. Burmester
    Laura C. Coates
    Stanley B. Cohen
    Yoshiya Tanaka
    Ivana Vranic
    Edward Nagy
    Irina Lazariciu
    All-shine Chen
    Kenneth Kwok
    Lara Fallon
    Cassandra Kinch
    Rheumatology and Therapy, 2024, 11 (1) : 221 - 222
12345